On October 30, Gelonhui reported that the lowest dose of novo-nordisk a/s's weight loss drug Wegovy has been listed as available on the website of the US health regulatory agencies. Since early 2022, several GLP-1 therapies from novo-nordisk a/s, such as Wegovy and diabetes drug Ozempic, have been on the shortage list of the Food and Drug Administration (FDA) in the usa. While all doses of Wegovy and Ozempic are now listed as available, they have not been removed from the regulatory agency's shortage list. The Food and Drug Administration removed eli lilly and co's weight loss drug from the shortage list in September.
诺和诺德减肥药Wegovy的最低剂量被FDA列为可用 仍在短缺名单中
The minimum dosage of novo-nordisk a/s weight loss drug Wegovy has been listed as available by the FDA, but it is still on the shortage list.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated